Tempus AI · 1 month ago
Key Account Director, Data and AI Apps
Tempus AI is focused on advancing the healthcare industry through precision medicine and AI solutions. They are seeking a Key Account Director, Data and AI Apps to develop and expand client relationships with leading biopharmaceutical organizations, driving the utilization of Tempus' Data and AI solutions.
Artificial Intelligence (AI)BiotechnologyHealth CareMachine LearningMedicalPrecision Medicine
Responsibilities
Develop and Drive global account strategy in coordination with our scientific and business operations teams
Meet and exceed revenue goals for All Tempus Data and AI apps product lines at the account while delivering on established strategic objectives for specific client accounts
Build and maintain executive and R&D relationships & drive our CXO strategy leveraging Tempus senior leadership
Become an expert in the partner’s strategy, pipeline and portfolio to proactively determine all areas that the Tempus platform could be leveraged for advancing innovation
Negotiate, secure and manage pull-through of contracts with assigned client accounts
Align the cross functional team of Product Specialists, Alliance Managers, Translational Researchers and Commercial Operations to most efficiently identify and deliver value at our clients
Partner with our clients to develop and announce impactful case studies leveraging the Tempus platform to advance precision medicine
Contribute to the development of the Life Sciences portfolio by providing feedback to Leadership regarding client responses and suggestions; maintain a solution-oriented mindset
Track progress against defined strategic objectives and revenue goals; review progress/setbacks frequently with broader Account Team and Tempus Leadership
Travel approximately 40% of working time, domestically and internationally
Other duties as assigned
Your day-to-day efforts will include but are not limited to client outreach, development and delivery of materials tailored to the client’s needs, client pitches, proposal writing, and contract negotiations
Qualification
Required
Entrepreneurial sales approach; thrives most in a high growth, rapidly evolving business environment
Proactive mindset that bridges ideas to implementable solutions, and can help move both internal and external stakeholders to quickly solve problems
Deep relationships with pharmaceutical stakeholders
Proven ability to navigate multi-faceted client organizations with repeated success
Ability to set strategies/tactics that are aggressive, but realizable
Wins followers with a positive and energetic approach to work and life; gains energy from solving difficult problems
Demonstrated ability to influence without authority (both with internal and external stakeholders)
Learning agility to adapt to a rapidly changing environment within Tempus
Exceptional account management, articulation of issues and an ability to navigate a wide range of stakeholders to solve problems
Minimum 5+ years in Business Development, Sales, and/or Consulting in the Life Sciences sector as lead account and relationship manager (Pharma / Biotech)
Proven track record of establishing credibility as a trusted advisor with clients
Experience negotiating and closing large and complex multi-year deals
Strong understanding of molecular and real-world data and artificial intelligence in drug discovery
Bachelor degree in a Science or Business discipline
Preferred
Preferably 5+ years working with companies who serviced Life Sciences companies in Research & Development and/or Real World Data
Advanced degree (MBA, PhD or Healthcare certification) desired
Benefits
Incentive compensation
Restricted stock units
Medical and other benefits depending on the position
Company
Tempus AI
Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data.
Funding
Current Stage
Public CompanyTotal Funding
$2.29BKey Investors
Ares ManagementGoogleBaillie Gifford
2025-06-30Post Ipo Debt· $650M
2025-02-19Post Ipo Debt· $300M
2024-06-14IPO
Recent News
Business Wire
2026-01-22
2026-01-13
Business Wire
2026-01-13
Company data provided by crunchbase